TSE:4570'
s ROE % Range Over the Past 10 Years
Min: -101.48 Med: -12.65 Max: 19.69
Current: 19.69
During the past 13 years, Immuno-Biological Laboratories Co's highest ROE % was 19.69%. The lowest was -101.48%. And the median was -12.65%.
TSE:4570's ROE % is ranked better than 92.49% of 1252
companies
in the Biotechnology industry
Industry Median: -38.145
vs TSE:4570: 19.69
Immuno-Biological Laboratories Co (TSE:4570) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Immuno-Biological Laboratories Co ROE % Related Terms
Immuno-Biological Laboratories Co ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Immuno-Biological Laboratories Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immuno-Biological Laboratories Co ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immuno-Biological Laboratories Co's ROE % distribution charts can be found below:
* The bar in red indicates where Immuno-Biological Laboratories Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Immuno-Biological Laboratories Co (TSE:4570) has a ROE % of 21.42% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Immuno-Biological Laboratories Co and its competitors. According to the industry distribution chart, Immuno-Biological Laboratories Co ranks #94 out of 1252 companies in the Biotechnology industry, placing it in the top 7.5%.
Is Immuno-Biological Laboratories Co's ROE % too high?
Immuno-Biological Laboratories Co's current ROE % is 21.42%. Based on the distribution chart, Immuno-Biological Laboratories Co ranks #94 out of 1252 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Immuno-Biological Laboratories Co has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immuno-Biological Laboratories Co's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immuno-Biological Laboratories Co ranks #94 out of 1252 companies for ROE %. This places Immuno-Biological Laboratories Co in the top 8% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Immuno-Biological Laboratories Co and its competitors. Immuno-Biological Laboratories Co's current ROE % is 21.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuno-Biological Laboratories Co stock overvalued right now?
Based on GuruFocus' analysis, Immuno-Biological Laboratories Co (TSE:4570) is currently considered Significantly Overvalued. The stock's GF Value™ is 円576.66, compared to a current price of 円969.00 — trading 68% above its estimated fair value. The current ROE % is 21.42%. Immuno-Biological Laboratories Co's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Immuno-Biological Laboratories Co (TSE:4570), the current ROE % is 21.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immuno-Biological Laboratories Co (TSE:4570) Overvalued in 2026?
Based on GuruFocus' analysis, Immuno-Biological Laboratories Co stock appears to be overvalued.
The current stock price of 円969.00 is trading 68% above its estimated GF Value™ of 円576.66.
GuruFocus considers Immuno-Biological Laboratories Co to be Significantly Overvalued.
Key valuation signals for TSE:4570:
ROE %: 21.42%
GF Value™: 円576.66 vs. price of 円969.00 (68% above fair value)
No single metric tells the full story. See the TSE:4570 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immuno-Biological Laboratories Co Business Description
Immuno-Biological Laboratories Co Ltd focuses on research and development. It researches, develops, manufacture and supplies various immunological research reagents, and customized services. It is engaged in research and development of materials used in diagnostic products and valuable seeds and technology for protein production using transgenic silkworm cocoons, which make it possible to create valuable proteins as well as antibodies. It works on clinical reagents for cancer research. Its research scientists are producing inflammatory cytokines, growth factors & antibodies for use against these cancers.
59GF Score
Get the complete analysis for TSE:4570
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4570 has been successfully added to your 
